[1] Yu H J, Liu J H, Liu W, et al. Metal-based nanomedicines for cancer theranostics[J]. Military Medical Research, 2025, 12(1):41.
[2] Patel L, Lindley C. Aprepitant-a novel NK1-receptor antagonist[J]. Expert Opinion on Pharmacotherapy, 2003, 4(12):2279‑2296.
[3] Schöppe J, Ehrenmann J, Klenk C, et al. Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists[J]. Nature Communications, 2019, 10(1):17.
[4] Inano H, Morimoto Y, Kawamura A, et al. Sustained antiemetic efficacy of fosnetupitant versus aprepitant in carboplatin-based chemotherapy: a retrospective observational study[J]. International Journal of Clinical Oncology, 2026, 31(2):301‑309.
[5] Enguer Öztürk S, Kaya Tilki E, Dikmen M. Anti-metastatic effects of aprepitant on glioblastoma cells: targeting the substance P/neurokinin-1 pathway[J]. Cancer Medicine, 2025, 14(15):e71148.
[6] Seto Y, Tokeshi S, Inoue D, et al. Diurnal variations of neurokinin-1 receptor define dosing time-dependent differences in antitumor effects of aprepitant in mice[J]. Journal of Pharmacological Sciences, 2025, 158(3):193‑198.
[7] Rezaei S, Darban R A, Javid H, et al. The therapeutic potential of aprepitant in glioblastoma cancer cells through redox modification[J]. BioMed Research International, 2022, 2022:8540403.
[8] Abdelzaher W Y, Kelleni M T, Adly M N, et al. Aprepitant alleviates acute lung injury in a rat model of hepatic ischemia‑reperfusion via NLRP3/IL-1β signaling pathway[J]. Scientific Reports, 2025, 15(1):40358.
[9] Yang Y, Zhou W, Xu X, et al. Aprepitant Inhibits JNK and p38/MAPK to attenuate inflammation and suppresses inflammatory pain[J]. Frontiers in Pharmacology, 2022, 12:811584.
[10] Hong X, Ma J, Zheng S, et al. Advances in the research and application of neurokinin-1 receptor antagonists[J]. Journal of Zhejiang University: Science B, 2024, 25(2):91‑105.
[11] Valdivia V, Recio R, Lerena P, et al. Biological evaluation of carbohydrate-based aprepitant analogs for neuroblastoma treatment[J]. European Journal of Medicinal Chemistry, 2024, 264:116021.
[12] Restaino A C, Walz A, Vermeer S J, et al. Functional neuronal circuits promote disease progression in cancer[J]. Science Advances, 2023, 9(19):eade4443.
[13] Rodriguez F D, Covenas R. Association of neurokinin-1 receptor signaling pathways with cancer[J]. Current Medicinal Chemistry, 2024, 31(39):6460‑6486.
[14] Ge H, Yang L, Chen C, et al. Human substance P interactions with G protein-coupled receptor NK1R observed by NMR in solution[J]. Journal of the American Chemical Society, 2025, 147(48):44114‑44122.
[15] 张渝, 杨昆, 黄江菊. P物质及其受体NK-1R在肿瘤中的研究进展[J]. 重庆医学, 2020, 49(24):4194‑4198.
[16] Letai A, De T H. Conventional chemotherapy: Millions of cures, unresolved therapeutic index[J]. Nature Reviews Cancer, 2025, 25(3):209‑218.
[17] Filetti M, Lombardi P, Giusti R, et al. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy‑induced nausea and vomiting: a systematic review and network meta-analysis[J]. Cancer Treatment Reviews, 2023, 115:102512.
[18] Grigio T R, Timmerman H, dos Santos N P, et al. Aprepitant and fosaprepitant as a prophylactic antiemetic for preventing postoperative nausea and vomiting after general anaesthesia: a systematic review and meta-analysis[J]. Clinics, 2025, 80:100783.
[19] Ham S Y, Shim Y H, Kim E H, et al. Aprepitant for antiemesis after laparoscopic gynaecological surgery: a randomised controlled trial[J]. European Journal of Anaesthesiology, 2016, 33(2):90‑95.
[20] Schmitt T, Goldschmidt H, Neben K, et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase Ⅲ trial[J]. Journal of Clinical Oncology, 2014, 32(30):3413‑3420.
[21] 中国抗癌协会肿瘤支持治疗专业委员会, 袁响林. 延迟性恶心呕吐防治中国专家共识(2023年版)[J]. 临床肿瘤学杂志, 2023, 28(5):442‑458.
[22] Muñoz M, Coveñas R. The neurokinin-1 receptor antagonist aprepitant, a new drug for the treatment of hematological malignancies: Focus on acute myeloid leukemia[J]. Journal of Clinical Medicine, 2020, 9(6):1659.
[23] Ho C M, Ho S T, Wang J J, et al. Dexamethasone has a central antiemetic mechanism in decerebrated cats[J]. Anesthesia & Analgesia, 2004, 99(3):734‑739.
[24] Khan W N, Tobias J D. Diphenhydramine: a review of its clinical applications and potential adverse effect profile[J]. The Journal of Pediatric Pharmacology and Therapeutics, 2025, 30(2):182‑190.
[25] Renner U D, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine[J]. Therapeutic Drug Monitoring, 2005, 27(5):655‑665.
[26] Ye J H, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-HT3 receptor antagonist and its applications in CNS-related disorders[J]. CNS Drug Reviews, 2001, 7(2):199‑213.
[27] Shen T J, Hanh V T, Nguyen T Q, et al. Repurposing the antiemetic metoclopramide as an antiviral against dengue virus infection in neuronal cells[J]. Frontiers in Cellular and Infection Microbiology, 2020, 10:606743.
[28] Zhong W, Shahbaz O, Teskey G, et al. Mechanisms of nausea and vomiting: current knowledge and recent advances in intracellular emetic signaling systems[J]. International Journal of Molecular Sciences, 2021, 22(11):5797.
[29] Higa G M, Auber M L, Altaha R, et al. 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy[J]. Journal of Oncology Pharmacy Practice, 2006, 12(4):201‑209.
[30] Stoutenburg J P, Raftopoulos H. Antiemetic studies on the NK1 receptor antagonist aprepitant[J]. Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw, 2004, 2(5):491‑497.
[31] Li Y Y, Sun Y, Liu B, et al. Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting[J]. Future Oncology, 2022, 18(20):2533‑2543.
[32] Wang D S, Hu M T, Wang Z Q, et al. Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women a randomized clinical trial[J]. JAMA Network Open, 2021, 4(4):e215250.
[33] Saito M, Iihara H, Shimokawa M, et al. Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo‑controlled trial[J]. The Lancet Oncology, 2025, 26(7):960‑970.
[34] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. Journal of the National Cancer Center, 2024, 4(1):47‑53.
[35] Xi Z, Dai R, Ze Y, et al. Traditional chinese medicine in lung cancer treatment[J]. Molecular Cancer, 2025, 24(1):57.
[36] Skoulidis F, Heymach J V. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy[J]. Nature Reviews Cancer, 2019, 19(9):495‑509.
[37] Jiang C Y, Xie S L, Jia K G, et al. Exploring cellular plasticity and resistance mechanisms in lung cancer: innovations and emerging therapies[J]. Journal of Pharmaceutical Analysis, 2025, 15(5):101179.
[38] Muñoz M, González Ortega A, Rosso M, et al. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists[J]. Peptides, 2012, 38(2):318‑325.
[39] Lucattelli M, Fineschi S, Geppetti P, et al. Neurokinin-1 receptor blockade and murine lung tumorigenesis[J]. American Journal of Respiratory and Critical Care Medicine, 2006, 174(6):674‑683.
[40] Zhang X W, Li L, Hu W Q, et al. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR[J]. Cell Death & Disease, 2022, 13(1):41.
[41] Muñoz M, Crespo J C, Crespo J P, et al. Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: a case report[J]. Molecular and Clinical Oncology, 2019, 11(1):50‑54.
[42] Simancas Racines D, Reytor González C, Frias Toral E, et al. Weighty matters: unraveling the impact of obesity on colorectal cancer and nutritional interventions[J]. Seminars in Cancer Biology, 2025, 114:29‑40.
[43] Favier S, Xiong W, Chalabi Dchar M, et al. Exploring and bypassing resistance to targeted therapies in colorectal cancer[J]. Biomedicine & Pharmacotherapy, 2025, 193:118741.
[44] Zhao H, Ming T, Tang S, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target[J]. Molecular Cancer, 2022, 21(1):144.
[45] Vermeulen L, De Sousa E Melo F, Van Der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment[J]. Nature Cell Biology, 2010, 12(5):468‑476.
[46] Shi Y, Wang X, Meng Y, et al. A novel mechanism of endoplasmic reticulum stress-and c-Myc-degradation-mediated therapeutic benefits of antineurokinin-1 receptor drugs in colorectal cancer[J]. Advanced Science, 2021, 8(21):e2101936.
[47] Ilmer M, Garnier A, Vykoukal J, et al. Targeting the neurokinin-1 receptor compromises canonical Wnt signaling in hepatoblastoma[J]. Molecular Cancer Therapeutics, 2015, 14(12):2712‑2721.
[48] Garnier A, Vykoukal J, Hubertus J, et al. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells[J]. International Journal of Oncology, 2015, 47(1):151‑160.
[49] Golestaneh M, Firoozrai M, Javid H, et al. The substance P/neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells[J]. Molecular Biology Reports, 2022, 49(6):4893‑4900.
[50] Ghahremanloo A, Javid H, Afshari A R, et al. Investigation of the role of neurokinin-1 receptor inhibition using aprepitant in the apoptotic cell death through PI3K/Akt/NF-κB signal transduction pathways in colon cancer cells[J]. BioMed Research International, 2021, 2021:1383878.
[51] Alalikhan A, Ebrahimi S, Aliee A, et al. The combined anti‑tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study[J]. Medical Oncology, 2024, 41(3):70.
[52] Lin S, Kuang M. RNA modification-mediated mRNA translation regulation in liver cancer: mechanisms and clinical perspectives[J]. Nature Reviews Gastroenterology & Hepatology, 2024, 21(4):267‑281.
[53] Gravitz L. Liver cancer[J]. Nature, 2014, 516(7529):S1.
[54] 李冬瑞, 杜成旭, 王文斌. 《原发性肝癌诊疗指南(2024年版)》更新解读[J]. 河北医科大学学报, 2025, 46(5):497‑501.
[55] 《原发性肝癌诊疗指南》编写专家委员会. 原发性肝癌诊疗指南(2024年版)[J]. 中国临床医学, 2024, 31(2):277‑334.
[56] Sedky H E, Elwany Y N, Alfy E S E, et al. Combined neurokinin-1 receptor antagonist and sorafenib is a promising approach for hepatocellular carcinoma therapy[J]. Egyptian Liver Journal, 2024, 14(1):57.
[57] Li Y, Wu J, Lu Q, et al. GA&HA-modified liposomes for co‑delivery of aprepitant and curcumin to inhibit drug-resistance and metastasis of hepatocellular carcinoma[J]. International Journal of Nanomedicine, 2022, 17:2559‑2575.
[58] Purcell R, Childs M, Maibach R, et al. Potential biomarkers for hepatoblastoma: results from the SIOPEL-3 study[J]. European Journal of Cancer, 2011, 48(12):1853‑1859.
[59] Wang Y, Jin R U, Xu J, et al. Harnessing technologies to unravel gastric cancer heterogeneity[J]. Trends in Cancer, 2025, 11(8):753‑769.
[60] Sun Y, Puspanathan P, Lim T, et al. Advances and challenges in gastric cancer testing: the role of biomarkers[J]. Cancer Biology & Medicine, 2025, 22(3):212‑230.
[61] Chen Y, Jia K, Xie Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis[J]. Journal of Hematology & Oncology, 2025, 18(1):42.
[62] Muñoz M, Rosso M, Coveñas R. The NK-1 receptor antagonist L-732, 138 induces apoptosis in human gastrointestinal cancer cell lines[J]. Pharmacological Reports, 2017, 69(4):696‑701.
[63] Nakamura M, Overby A, Uehara A, et al. Significance of cholinergic and peptidergic nerves in stress-induced ulcer and MALT lymphoma formation[J]. Current Pharmaceutical Design, 2017, 23(27):3993‑3996.
[64] Wang Y, Sun H, Li G, et al. Impact of maternal and offspring smoking and breastfeeding on oesophageal cancer in adult offspring[J]. Nature Communications, 2025, 16(1):938.
[65] Yang H, Li X, Yang W. Advances in targeted therapy and immunotherapy for esophageal cancer[J]. Chinese Medical Journal, 2023, 136(16):1910‑1922.
[66] Wang F, Liu S, Liu J, et al. SP promotes cell proliferation in esophageal squamous cell carcinoma through the NK1R/Hes1 axis[J]. Biochemical and Biophysical Research Communications, 2019, 514(4):1210‑1216.
[67] Dong J, Feng F, Xu G, et al. Elevated SP/NK-1R in esophageal carcinoma promotes esophageal carcinoma cell proliferation and migration[J]. Gene, 2015, 560(2):205‑210.
[68] Zheng Y, Sang M X, Liu F, et al. Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin-1 receptor[J]. Oncology Reports, 2023, 50(1):131.
[69] Javid H, Afshari A R, Avval F Z, et al. Aprepitant promotes caspase-dependent apoptotic cell death and G2/M arrest through PI3K/Akt/NF-κB axis in cancer stem-like esophageal squamous cell carcinoma spheres[J]. BioMed Research International, 2021, 2021:8808214.
[70] Wan Y, Li G, Cui G, et al. Reprogramming of thyroid cancer metabolism: from mechanism to therapeutic strategy[J]. Molecular Cancer, 2025, 24(1):74.
[71] Cherifi F, Awada A. Molecular oncology of iodine refractory thyroid cancer current therapies and perspective[J]. Critical Reviews in Oncology Hematology, 2025, 209:104679.
[72] Skrabanek P, Cannon D, Dempsey J, et al. Substance P in medullary carcinoma of the thyroid[J]. Experientia, 1979, 35(9):1259‑1260.
[73] Holm R, Sobrinho Simões M, Nesland J M, et al. Medullary carcinoma of the thyroid gland: an immunocytochemical study[J]. Ultrastructural Pathology, 1985, 8(1):25‑41.
[74] Hennig I M, Laissue J A, Horisberger U, et al. Substance P receptors in human primary neoplasms: tumoral and vascular localization[J]. International Journal of Cancer, 1995, 61(6):786‑792.
[75] Davoodian M, Boroumand N, Mehrabi Bahar M, et al. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer[J]. Molecular Biology Reports, 2019, 46(1):1285‑1293.
[76] Isorna I, González Moles M Á, Muñoz M, et al. Substance P and neurokinin-1 receptor system in thyroid cancer: potential targets for new molecular therapies[J]. Journal of Clinical Medicine, 2023, 12(19):6409.
[77] Isorna I, Esteban F, Solanellas J, et al. The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study[J]. European Journal of Histochemistry, 2020, 64(2):139‑147.
[78] Calonge N, Petitti D B, Dewitt T G, et al. Screening for breast cancer: US preventive services task force recommendation statement[J]. Annals of Internal Medicine, 2009, 151(10):716‑726.
[79] Liang Y R, Zhang H W, Song X J, et al. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets[J]. Seminars in Cancer Biology, 2020, 60:14‑27.
[80] Garcia Recio S, Fuster G, Fernandez Nogueira P, et al. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer[J]. Cancer Research, 2013, 73(21):6424‑6434.
[81] Mehboob R, Gilani S A, Hassan A, et al. Prognostic significance of substance P/neurokinin 1 receptor and its association with hormonal receptors in breast carcinoma[J]. BioMed Research International, 2021, 2021:5577820.
[82] Garcia Recio S, Pastor Arroyo E M, Marín Aguilera M, et al. The transmodulation of HER2 and EGFR by substance P in breast cancer cells requires c-Src and metalloproteinase activation[J]. PLoS One, 2015, 10(6):e0129661.
[83] Wang L, Wang N, Zhang R, et al. TGFβ regulates NK1R-Tr to affect the proliferation and apoptosis of breast cancer cells[J]. Life Sciences, 2020, 256:117674.
[84] Wellenstein M D, Coffelt S B, Duits D E M, et al. Loss of p53 triggers Wnt-dependent systemic inflammation to drive breast cancer metastasis[J]. Nature, 2019, 572(7770):538‑542.
[85] Lim J E, Chung E, Son Y. A neuropeptide, substance P, directly induces tissue-repairing M2 like macrophages by activating the PI3K/Akt/mTOR pathway even in the presence of IFNγ[J]. Scientific Reports, 2017, 7(1):9417.
[86] Muñoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug[J]. Investigational New Drugs, 2010, 28(2):187‑193.
[87] Robinson P, Coveñas R, Muñoz M. Combination therapy of chemotherapy or radiotherapy and the neurokinin-1 receptor antagonist aprepitant: a new antitumor strategy?[J]. Current Medicinal Chemistry, 2023, 30(16):1798‑1812.
[88] Coveñas R, Rodríguez F D, Robinson P, et al. The repurposing of non-peptide neurokinin-1 receptor antagonists as antitumor drugs: an urgent challenge for aprepitant[J]. International Journal of Molecular Sciences, 2023, 24(21):15936.
)
